Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Nutr. clín. diet. hosp ; 41(3): 158-170, 2021. tab, graf
Article in Spanish | IBECS | ID: ibc-225827

ABSTRACT

Introdução: Pacientes com doenças como lúpus eritematoso sistêmico (LES) e artrite reumatoide (AR) são especialmente predispostos a desenvolver sarcopenia à luz do estadopró-inflamatório subjacente e da diminuição do uso muscularde vido à inatividade e à dor. Objetivo: Verificar a correlação do risco de sarcopenia com o estado nutricional em portadores de lúpus eritematoso sistêmico e artrite reumatoide assistidos em um centro de referência no Nordeste. Metodologia: Estudo transversal com 114 pacientes com idade entre 18 a 85 anos. Foram coletadas informações clínicas e dados antropométricos e realizada avaliação da capacidade funcional através do instrumento SARC-F juntamente àforça de preensão manual (FPM). A provável sarcopenia foi adotada com o score de SARC-F com risco e FPM inadequada. Resultados: A média de idade encontrada no grupo de adultos foi 41,89 (± 12,02,DP), enquanto no grupo de idosos essa média foi de 70,05 (± 8,47DP). Houve uma prevalência de excesso de peso de 57,89% nos adultos e eutróficos nos idosos 36,84%. A avaliação de risco de sarcopenia pelo SARC-F juntamente com a FPM identificou a possível sarcopenia em 34,06% no grupo de adultos. Nos idosos, foi encontrada uma correlação muito forte entre a variável SARC-F e FPM(r=1,000) p=0,000. Conclusão: Houve prevalência de adultos com excesso de peso e no grupo de idosos, eutrofia. Em relação a força da pressão manual evidencio-se prevalência na diminuição da força muscular na população estudada. (AU)


Introduction: Patients with diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are especially predisposed to develop sarcopenia in light of the underlying pro-inflammatory state and decreased muscle use due to inactivity and pain. Objective: To verify the correlation of sarcopenia risk with nutritional status in patients with systemic lupus erythematosus and rheumatoid arthritis assisted at a referral center in the Northeast. Methodology: Cross-sectional study with 114 patients aged between 18 and 85 years. Clinical information and anthropometric data were collected, and functional capacity was assessed using the SARC-F instrument along with hand gripstrength (HGS). A probable sarcopenia was adopted with the SARC-F score with risk and inadequate HGS. Results: The mean age found in the group of adults was 41.89 (± 12.02, SD), while in the group of elderly people, this mean was 70.05 (± 8.47SD). There is a prevalence of overweight of 57.89% in adults and eutrophic in the elderly 36.84%. The SARC-F risk assessment of sarcopenia together with an HGS identified possible sarcopenia in 34.06% in the adult group. In the elderly, a very strong correlation was found between the variable SARC-F and HGS (r = 1,000) p = 0.000. Conclusion: There is a prevalence of overweight in adults, and prevalence of normal weight in the elderly group. About the strength of manual pressure, there is evidence of decreased muscle strength in the population studied. (AU)


Subject(s)
Humans , Male , Female , Young Adult , Adult , Middle Aged , Aged , Aged, 80 and over , Nutritional Status , Lupus Erythematosus, Systemic , Arthritis, Rheumatoid , Sarcopenia/epidemiology , Cross-Sectional Studies , Epidemiology, Descriptive , Prospective Studies , Brazil , Prevalence , Correlation of Data
2.
Rev Bras Reumatol Engl Ed ; 57 Suppl 2: 421-437, 2017.
Article in English, Portuguese | MEDLINE | ID: mdl-28751131

ABSTRACT

Chikungunya fever has become a relevant public health problem in countries where epidemics occur. Until 2013, only imported cases occurred in the Americas, but in October of that year, the first cases were reported in Saint Marin island in the Caribbean. The first autochthonous cases were confirmed in Brazil in September 2014; until epidemiological week 37 of 2016, 236,287 probable cases of infection with Chikungunya virus had been registered, 116,523 of which had serological confirmation. Environmental changes caused by humans, disorderly urban growth and an ever-increasing number of international travelers were described as the factors responsible for the emergence of large-scale epidemics. Clinically characterized by fever and joint pain in the acute stage, approximately half of patients progress to the chronic stage (beyond 3 months), which is accompanied by persistent and disabling pain. The aim of the present study was to formulate recommendations for the diagnosis and treatment of Chikungunya fever in Brazil. A literature review was performed in the MEDLINE, SciELO and PubMed databases to ground the decisions for recommendations. The degree of concordance among experts was established through the Delphi method, involving 2 in-person meetings and several online voting rounds. In total, 25 recommendations were formulated and divided into 3 thematic groups: (1) clinical, laboratory and imaging diagnosis; (2) special situations; and (3) treatment. The first 2 themes are presented in part 1, and treatment is presented in part 2.


Subject(s)
Chikungunya Fever/diagnosis , Brazil , Chikungunya Fever/physiopathology , Chikungunya Fever/therapy , Consensus , Delphi Technique , Female , Humans , Male , Pregnancy , Pregnancy Complications, Infectious/diagnosis , Pregnancy Complications, Infectious/therapy , Rheumatology , Societies, Medical
3.
Rev. bras. reumatol ; 57(supl.2): s421-s437, 2017. tab
Article in English | LILACS | ID: biblio-899486

ABSTRACT

Abstract Chikungunya fever has become a relevant public health problem in countries where epidemics occur. Until 2013, only imported cases occurred in the Americas, but in October of that year, the first cases were reported in Saint Marin island in the Caribbean. The first autochthonous cases were confirmed in Brazil in September 2014; until epidemiological week 37 of 2016, 236,287 probable cases of infection with Chikungunya virus had been registered, 116,523 of which had serological confirmation. Environmental changes caused by humans, disorderly urban growth and an ever-increasing number of international travelers were described as the factors responsible for the emergence of large-scale epidemics. Clinically characterized by fever and joint pain in the acute stage, approximately half of patients progress to the chronic stage (beyond 3 months), which is accompanied by persistent and disabling pain. The aim of the present study was to formulate recommendations for the diagnosis and treatment of Chikungunya fever in Brazil. A literature review was performed in the MEDLINE, SciELO and PubMed databases to ground the decisions for recommendations. The degree of concordance among experts was established through the Delphi method, involving 2 in-person meetings and several online voting rounds. In total, 25 recommendations were formulated and divided into 3 thematic groups: (1) clinical, laboratory and imaging diagnosis; (2) special situations; and (3) treatment. The first 2 themes are presented in part 1, and treatment is presented in part 2.


Resumo A febre chikungunya tem se tornado um importante problema de saúde pública nos países onde ocorrem as epidemias. Até 2013, as Américas haviam registrado apenas casos importados quando, em outubro desse mesmo ano, foram notificados os primeiros casos na Ilha de Saint Martin, no Caribe. No Brasil, os primeiros relatos autóctones foram confirmados em setembro de 2014 e até a semana epidemiológica 37 de 2016 já haviam sido registrados 236.287 casos prováveis de infecção pelo chikungunya vírus (CHIKV), 116.523 confirmados sorologicamente. As mudanças ambientais causadas pelo homem, o crescimento urbano desordenado e o número cada vez maior de viagens internacionais têm sido apontados como os fatores responsáveis pela reemergência de epidemias em grande escala. Caracterizada clinicamente por febre e dor articular na fase aguda, em cerca de metade dos casos existe evolução para a fase crônica (além de três meses), com dor persistente e incapacitante. O objetivo deste trabalho foi elaborar recomendações para diagnóstico e tratamento da febre chikungunya no Brasil. Para isso, foi feita revisão da literatura nas bases de dados Medline, SciELO e PubMed, para dar apoio às decisões tomadas para definir as recomendações. Para a definição do grau de concordância foi feita uma metodologia Delphi, em duas reuniões presenciais e várias rodadas de votação on line. Foram geradas 25 recomendações, divididas em três grupos temáticos: (1) diagnóstico clínico, laboratorial e por imagem; (2) situações especiais e (3) tratamento. Na primeira parte estão os dois primeiros temas e o tratamento na segunda.


Subject(s)
Humans , Male , Female , Pregnancy , Chikungunya Fever/diagnosis , Pregnancy Complications, Infectious/diagnosis , Pregnancy Complications, Infectious/therapy , Rheumatology , Societies, Medical , Brazil , Delphi Technique , Consensus , Chikungunya Fever/physiopathology , Chikungunya Fever/therapy
4.
Rev. bras. reumatol ; 57(supl.2): s438-s451, 2017. tab, graf
Article in English | LILACS | ID: biblio-899488

ABSTRACT

Abstract Chikungunya fever has become an important public health problem in countries where epidemics occur because half of the cases progress to chronic, persistent and debilitating arthritis. Literature data on specific therapies at the various phases of arthropathy caused by chikungunya virus (CHIKV) infection are limited, lacking quality randomized trials assessing the efficacies of different therapies. There are a few studies on the treatment of musculoskeletal manifestations of chikungunya fever, but these studies have important methodological limitations. The data currently available preclude conclusions favorable or contrary to specific therapies, or an adequate comparison between the different drugs used. The objective of this study was to develop recommendations for the treatment of chikungunya fever in Brazil. A literature review was performed via evidence-based selection of articles in the databases Medline, SciELO, PubMed and Embase and conference proceedings abstracts, in addition to expert opinions to support decision-making in defining recommendations. The Delphi method was used to define the degrees of agreement in 2 face-to-face meetings and several online voting rounds. This study is part 2 of the Recommendations of the Brazilian Society of Rheumatology (Sociedade Brasileira de Reumatologia - SBR) for the Diagnosis and Treatment of chikungunya fever and specifically addresses treatment.


Resumo A febre chikungunya tem se tornado um importante problema de saúde pública nos países onde ocorrem as epidemias, visto que metade dos casos evolui com artrite crônica, persistente e incapacitante. Os dados na literatura sobre terapêuticas específicas nas diversas fases da artropatia ocasionada pela infecção pelo vírus chikungunya (CHIKV) são limitados, não existem estudos randomizados de qualidade que avaliem a eficácia das diferentes terapias. Há algumas poucas publicações sobre o tratamento das manifestações musculoesqueléticas da febre chikungunya, porém com importantes limitações metodológicas. Os dados atualmente disponíveis não permitem conclusões favoráveis ou contrárias a terapêuticas específicas, bem como uma adequada avaliação quanto à superioridade entre as diferentes medicações empregadas. O objetivo deste trabalho foi elaborar recomendações para o tratamento da febre chikungunya no Brasil. Foi feita uma revisão da literatura com seleção de artigos baseados em evidência, nas bases de dados Medline, SciELO, PubMed e Embase e de resumos de anais de congressos, além da opinião dos especialistas para dar apoio às decisões tomadas para definir as recomendações. Para a definição do grau de concordância foi feita uma metodologia Delphi, em duas reuniões presenciais e várias rodadas de votação on line. Este artigo refere-se à parte 2 das Recomendações da Sociedade Brasileira de Reumatologia para Diagnóstico e Tratamento da Febre Chikungunya, que trata especificamente do tratamento.


Subject(s)
Humans , Chikungunya Fever/drug therapy , Rheumatology , Societies, Medical , Brazil , Delphi Technique , Physical Therapy Modalities , Disease Progression , Consensus , Chikungunya Fever/diagnosis , Chikungunya Fever/rehabilitation
5.
Clinics ; 68(6): 766-771, jun. 2013. tab, graf
Article in English | LILACS | ID: lil-676937

ABSTRACT

OBJECTIVES: Hydroxychloroquine is an antimalarial agent that has been used in systemic lupus erythematosus and rheumatoid arthritis treatment for many years. Recently, novel mechanisms of action have been proposed, thereby broadening the therapeutic perspective of this medication. The purpose of this study was to evaluate the immunomodulatory activity of hydroxychloroquine in T helper 17 (Th17) cytokines in healthy individuals and patients. METHODS: Eighteen female patients with systemic lupus erythematosus (mean age 39.0±12.9 years) and 13 female patients with rheumatoid arthritis (mean age 51.5±7.7 years) were recruited from Universidade Federal de Pernambuco-Brazil. The patients were included after fulfilling four classification criteria for systemic lupus erythematosus or rheumatoid arthritis from the American College of Rheumatology. After being stimulated with phorbol 12-myristate 13-acetate and ionomycin in the absence or presence of different concentrations of hydroxychloroquine, the interleukin 6, 17 and 22 levels were quantified with an enzyme-linked immunosorbent assay in culture supernatants of peripheral blood mononuclear cells from healthy individuals and patients. RESULTS: We demonstrated that in peripheral blood mononuclear cells from healthy volunteers and in systemic lupus erythematosus and rheumatoid arthritis patients, there was a significant reduction in the IL-6, IL-17 and IL-22 supernatant levels after adding hydroxychloroquine. CONCLUSIONS Our in vitro results demonstrated that hydroxychloroquine inhibits IL-6, IL-17 and IL-22 production and contributes to a better understanding of the mechanism of action of this medication. .


Subject(s)
Adult , Aged , Female , Humans , Middle Aged , Young Adult , Antimalarials/pharmacology , Arthritis, Rheumatoid/blood , Hydroxychloroquine/pharmacology , Interleukins/blood , Lupus Erythematosus, Systemic/blood , /drug effects , Antimalarials/therapeutic use , Arthritis, Rheumatoid/drug therapy , Case-Control Studies , Cell Count , Cells, Cultured , Enzyme-Linked Immunosorbent Assay , Hydroxychloroquine/therapeutic use , /blood , /blood , Lupus Erythematosus, Systemic/drug therapy , Statistics, Nonparametric , /immunology
6.
Rev. bras. reumatol ; 52(1): 60-65, jan.-fev. 2012. tab
Article in Portuguese | LILACS | ID: lil-611471

ABSTRACT

INTRODUÇÃO: O papel imunorregulatório da vitamina D tem sido alvo de um crescente número de estudos em pacientes com lúpus eritematoso sistêmico (LES). Objetivos: Determinar os níveis séricos de 25-hidroxivitamina D3 [25(OH)D] em pacientes com LES e verificar a associação da insuficiência/deficiência de 25(OH)D com parâmetros clínicos e laboratoriais. MÉTODOS:Estudo de corte transversal, prospectivo, realizado no ambulatório de LES do Serviço de Reumatologia do Hospital das Clínicas da Universidade Federal de Pernambuco. Foram incluídos 78 pacientes portadores de LES e 64 voluntários (grupo de comparação) pareados por gênero e idade. RESULTADOS: Constatou-se insuficiência/deficiência de 25(OH)D em 45 (57,7 por cento) pacientes com LES e em 25 (39 por cento) indivíduos do grupo de comparação. Os níveis séricos médios de 25(OH)D foram 29,3 ng/mL (6,1-55,2 ng/mL) nos pacientes com LES e 33,12 ng/mL (15,9-63,8 ng/mL) no grupo de comparação; essa diferença é considerada estatisticamente significante (P = 0,041). Não houve diferença estatisticamente significante entre as médias de idade dos dois grupos. Não houve associação estatisticamente significante entre insuficiência/deficiência de 25(OH)D e tempo de diagnóstico, atividade de doença (SLEDAI > 6), fadiga, uso de corticosteroides e de antimaláricos e anti-DNA. CONCLUSÕES:Foi constatada alta prevalência de insuficiência/deficiência de 25(OH)D nos pacientes com LES (57,7 por cento), com diferença estatisticamente significante em relação ao grupo de comparação. Não evidenciamos associação de insuficiência/deficiência de vitamina D com as variáveis clínicas e laboratoriais estudadas. Os autores enfatizam a importância da determinação dos níveis séricos de 25(OH)D em todos os pacientes com LES, independente de onde residam e do tempo de diagnóstico da doença.


INTRODUCTION: The immunoregulatory role of vitamin D has been the object of a growing number of studies in patients with systemic lupus erythematosus (SLE). OBJECTIVES: To determine the serum levels of 25-hydroxyvitamin D3 [25(OH) D] in patients with SLE, and to assess the association of 25(OH)D insufficiency/deficiency with clinical parameters and laboratory tests. METHODS: Cross-sectional, prospective study performed at the SLE Clinic, Department of Rheumatology, Hospital das Clínicas, Universidade Federal de Pernambuco with convenience sampling, including 78 patients with SLE and 64 volunteers (comparison group), matched by gender and age. RESULTS: Insufficiency/deficiency of 25(OH)D was found in 45 (57.7 percent) patients with SLE and 25 (39 percent) individuals in the comparison group. The mean serum levels of 25(OH)D were 29.3 ng/mL (6.1-55.2 ng/mL) in patients with SLE and 33.12 ng/mL (15.9-63.8 ng/mL) in the comparison group, and this difference was statistically significant (P = 0.041). No statistically significant difference was observed between the mean ages of both groups. No statistically significant association was observed between 25(OH)D insufficiency/deficiency and the following: time to diagnosis; disease activity (SLEDAI > 6); fatigue; use of corticosteroids and antimalarials; and anti-DNA. CONCLUSIONS: High prevalence of 25(OH)D insufficiency/deficiency was found in patients with SLE (57.7 percent), with statistically significant difference as compared with the comparison group. No association of vitamin D insufficiency/deficiency was observed with the clinical variables and laboratory tests studied. The authors emphasize the importance of determining 25(OH)D serum levels in all patients with SLE, regardless of where they live and time to disease diagnosis.


Subject(s)
Adult , Female , Humans , Male , Calcifediol/blood , Lupus Erythematosus, Systemic/complications , Vitamin D Deficiency/etiology , Cross-Sectional Studies , Lupus Erythematosus, Systemic/blood , Prospective Studies
7.
Rev Bras Reumatol ; 52(1): 60-5, 2012.
Article in English, Portuguese | MEDLINE | ID: mdl-22286646

ABSTRACT

INTRODUCTION: The immunoregulatory role of vitamin D has been the object of a growing number of studies in patients with systemic lupus erythematosus (SLE). OBJECTIVES: To determine the serum levels of 25-hydroxyvitamin D3 [25(OH) D] in patients with SLE, and to assess the association of 25(OH)D insufficiency/deficiency with clinical parameters and laboratory tests. METHODS: Cross-sectional, prospective study performed at the SLE Clinic, Department of Rheumatology, Hospital das Clínicas, Universidade Federal de Pernambuco with convenience sampling, including 78 patients with SLE and 64 volunteers (comparison group), matched by gender and age. RESULTS: Insufficiency/deficiency of 25(OH)D was found in 45 (57.7%) patients with SLE and 25 (39%) individuals in the comparison group. The mean serum levels of 25(OH)D were 29.3 ng/mL (6.1-55.2 ng/mL) in patients with SLE and 33.12 ng/mL (15.9-63.8 ng/mL) in the comparison group, and this difference was statistically significant (P = 0.041). No statistically significant difference was observed between the mean ages of both groups. No statistically significant association was observed between 25(OH)D insufficiency/deficiency and the following: time to diagnosis; disease activity (SLEDAI > 6); fatigue; use of corticosteroids and antimalarials; and anti-DNA. CONCLUSIONS: High prevalence of 25(OH)D insufficiency/deficiency was found in patients with SLE (57.7%), with statistically significant difference as compared with the comparison group. No association of vitamin D insufficiency/deficiency was observed with the clinical variables and laboratory tests studied. The authors emphasize the importance of determining 25(OH)D serum levels in all patients with SLE, regardless of where they live and time to disease diagnosis.


Subject(s)
Calcifediol/blood , Lupus Erythematosus, Systemic/complications , Vitamin D Deficiency/etiology , Adult , Cross-Sectional Studies , Female , Humans , Lupus Erythematosus, Systemic/blood , Male , Prospective Studies
8.
RBM rev. bras. med ; 67(esp.4)ago. 2010.
Article in Portuguese | LILACS | ID: lil-560122

ABSTRACT

A caquexia reumatoide é caracterizada pela perda involuntária de massa magra, predominantemente de músculo-esquelético, que ocorre também em vísceras e sistema imune, com massa gorda estável ou pouco elevada, e com pequena ou nenhuma perda de peso. Constitui uma condição pouco reconhecida na prática clínica e, nos casos severos, com importante perda de peso, há aumento da morbidade, com mortalidade prematura, embora a perda de massa muscular com um índice de massa corpórea normal também esteja associada com uma resposta clínica insatisfatória. A causa é multifatorial, incluindo a produção acentuada de citocinas, entre elas o TNF-alfa, e diminuição da atividade física. A composição corporal pode ser analisada utilizando as medidas antropométricas, densitometria de corpo total e outras técnicas, mas os resultados devem ser interpretados com cautela. Atualmente, a ressonância magnética tem sido estudada como importante exame para definir, com mais confiança, a massa muscular e a distribuição de gordura corporal. A caquexia apresenta pouca resposta à dieta de forma isolada, mas treinamento de resistência progressivo e terapia com antifator de necrose tumoral a são medidas que prometem melhorar esta manifestação extra-articular incapacitante da artrite reumatoide.

SELECTION OF CITATIONS
SEARCH DETAIL
...